Over the last few decades, alternative approaches to open surgery for local treatment of genitourinary cancers have been developed and progressively included in clinical practice. Among those include robotic surgery, radiation therapy and ablation techniques which represents the most successful and promising alternatives. Specifically, robotic surgery, initially applied to urology in the early 2000s, has now also emerged as a viable alternative to open surgery in many uro-oncological applications including complex surgical procedures such as totally intracorporeal urinary diversion and inferior vena cava thrombus surgery. Similarly, radiation therapy which includes or excludes chemotherapy and/or hormonal therapy has become a valid alternative to radical surgery procedures. Last but not least, ablation techniques including cryoablation, HIFU and radiofrequency ablation represent an innovative approach to target and destroy tumor foci guided by imaging as an alternative to major surgical procedures.
All these innovations of developing treatment is aimed at reducing the perioperative morbidity, hospital stay and costs without affecting long-term oncologic outcomes. Some of these treatment modalities have been already explored and proved successful in some scenarios (i.e., robot-assisted radical prostatectomy and radiotherapy for prostate cancer). Nonetheless, continuous refinements have been developing in the attempt to prove the benefit of more pioneering approaches (i.e., tri-modality therapy for bladder cancer, ablation techniques for prostate cancer or small renal masses), or to maximize benefit of these new treatment modalities (i.e., single-port robot-assisted radical prostatectomy, ICG-guided robot-assisted partial nephrectomy).
To address the continuous expansion of these new treatment modalities, this Research Topics aims to focus on innovative treatment modalities for clinical practice in genitourinary malignancies. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Over the last few decades, alternative approaches to open surgery for local treatment of genitourinary cancers have been developed and progressively included in clinical practice. Among those include robotic surgery, radiation therapy and ablation techniques which represents the most successful and promising alternatives. Specifically, robotic surgery, initially applied to urology in the early 2000s, has now also emerged as a viable alternative to open surgery in many uro-oncological applications including complex surgical procedures such as totally intracorporeal urinary diversion and inferior vena cava thrombus surgery. Similarly, radiation therapy which includes or excludes chemotherapy and/or hormonal therapy has become a valid alternative to radical surgery procedures. Last but not least, ablation techniques including cryoablation, HIFU and radiofrequency ablation represent an innovative approach to target and destroy tumor foci guided by imaging as an alternative to major surgical procedures.
All these innovations of developing treatment is aimed at reducing the perioperative morbidity, hospital stay and costs without affecting long-term oncologic outcomes. Some of these treatment modalities have been already explored and proved successful in some scenarios (i.e., robot-assisted radical prostatectomy and radiotherapy for prostate cancer). Nonetheless, continuous refinements have been developing in the attempt to prove the benefit of more pioneering approaches (i.e., tri-modality therapy for bladder cancer, ablation techniques for prostate cancer or small renal masses), or to maximize benefit of these new treatment modalities (i.e., single-port robot-assisted radical prostatectomy, ICG-guided robot-assisted partial nephrectomy).
To address the continuous expansion of these new treatment modalities, this Research Topics aims to focus on innovative treatment modalities for clinical practice in genitourinary malignancies. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
